#USA #Anixa Biosciences #San Jose #oncology #Breast Cancer Vaccine

Anixa Biosciences Secures Patent for Breast Cancer Vaccine

Anixa Biosciences, Inc. is making significant strides in the realm of cancer prevention, particularly in breast cancer treatment. The biotechnology company, based in San Jose, California, recently announced that the U.S. Patent and Trademark Office (USPTO) will issue Patent Number 12,370,244 on July 29, 2025. This vital patent expands the company’s intellectual property rights over its innovative breast cancer vaccine technology, a breakthrough that could redefine how we approach preventive oncology.

The patent covers novel methods for immunizing patients against breast cancer through a composition that includes human α-lactalbumin protein. This specific protein is not only prevalent in breast tissue during lactation but is also found in certain types of breast cancers. This makes it a promising target for immunoprevention strategies, which ultimately aim to stimulate the immune system to eliminate pre-malignant and malignant cells expressing this protein.

Developed in collaboration with the renowned Cleveland Clinic, Anixa's breast cancer vaccine represents a pioneering approach to combating one of the most diagnosed cancers among women globally. Projections indicate that there will be over 297,000 new cases of invasive breast cancer in the United States by 2025, a sobering statistic highlighting the urgent need for effective preventive measures. Currently, no FDA-approved vaccine exists to prevent breast cancer, underscoring a significant gap in the field of oncology.

By targeting the α-lactalbumin protein, Anixa's investigational vaccine aims to provide long-lasting immune protection while limiting damage to normal tissues. This characteristic is particularly important as it seeks to minimize off-target effects that are often associated with other forms of cancer treatment.

The potential market for Anixa's breast cancer vaccine is substantial, particularly among women at high risk of developing triple-negative breast cancer (TNBC), an aggressive subtype of the disease with limited treatment options. Analysts project a multi-billion dollar opportunity in this sector, especially as clinical data and regulatory frameworks continue to evolve.

Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, shared his enthusiasm for this development, stating, "Our breast cancer vaccine program is a cornerstone of our long-term strategy to develop next-generation preventive immunotherapies, and this patent issuance further secures our leadership in this field." The expansion of their patent portfolio, now extending well into the mid-2040s, solidifies Anixa's position in the industry and enhances its capacity to deliver innovative solutions to combat cancer.

Apart from the vaccine program, Anixa is involved in the development of various immunotherapies aimed at treating and preventing other cancers, including ovarian cancer, partnering with the Moffitt Cancer Center. Their approach utilizes a unique CAR-T technology known as chimeric endocrine receptor-T cell (CER-T) therapy, which distinguishes itself from traditional cell therapies.

As Anixa moves forward, the company's strategic collaborations with top-tier research institutions will continue to facilitate the advancement of its groundbreaking technologies in cancer treatment. The promising developments in their breast cancer vaccine provide hope for effective preventive measures, transforming the landscape of breast cancer treatment and prevention.

To stay updated on Anixa Biosciences and their innovative research, visit their official website at anixa.com or follow them on social media platforms.